Navigation Links
BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Date:2/7/2008

SAN ANTONIO, Feb. 7 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. today announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Based on prior studies, BioNumerik believes Karenitecin has the potential for fewer side-effects, better efficacy, and less susceptibility to drug resistance mechanisms compared to the currently marketed camptothecin drugs.

The Phase III trial has been designed as a global, randomized, multi-center open label trial to prospectively evaluate the safety and efficacy of Karenitecin compared to the chemotherapy drug topotecan (also known as Hycamtin(R)). Either Karenitecin or topotecan will be given intravenously daily for 5 consecutive days repeated every 3 weeks to advanced ovarian cancer patients who have previously been treated with platinum and taxane chemotherapy drugs but have become resistant to the platinum/taxane therapy. BioNumerik has received written agreement from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) regarding the clinical trial design and protocol.

Four Phase II clinical trials of intravenously administered Karenitecin have been completed in the U.S. in patients with advanced ovarian cancer, metastatic malignant melanoma, advanced non-small cell lung cancer, and primary brain tumors. BioNumerik has also initiated a Phase I clinical trial to evaluate the safety and effectiveness of an orally administered Karenitecin formulation. Based on prior studies, BioNumerik believes Karenitecin may have the following potential advantages over currently marketed camptothecins:
-- Comparable or improved effectiveness in the treatment of certain

cancers, with a potentially improved
'/>"/>

SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Kendle (Nasdaq: KNDL ), a leading, global full-service clinical research organization, today ... on June 23, 2010 , at the InterContinental Hotel in Boston . ... Kendle,s formal presentation will be given by Chairman ... Time . , , , ...
... June 17 Brainlab AG today announced that it ... business unit of the Toshiba Group, to integrate its Aquilion™ LB ... operating room (OR). , , ... Stephan Holl , Chief Operating Officer, Brainlab, indicated that ...
Cached Medicine Technology:Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 3
(Date:7/11/2014)... Austin, TX (PRWEB) July 11, 2014 ... to their staff. Jim Siddons joins the agency as ... Siddons graduated in 1994 with a Bachelor’s Degree in ... years of industry experience and will manage everything from ... bonds for trucking to the specialized needs for those ...
(Date:7/11/2014)... scientists have been trying to unravel mechanisms that guide ... that generate all blood cells including our immune system. ... because they can only be found in the bone ... a culture dish. Now a group of scientists from ... (Technische Universitt Dresden) was able to generate a mouse ...
(Date:7/11/2014)... July 11, 2014 With the arrival ... men seeking cosmetic surgery and hair transplant procedures, up ... an expansive range of medical tourism destinations, the company ... surgery costs and achieve the look they have ... as the top name in the medical tourism industry, ...
(Date:7/11/2014)... 11, 2014 Fadhits.com, the distinguished wedding ... assortment of lace holiday dresses . To top ... now offered at discounted prices, up to 65% off. ... enjoy this special offer. , Fadhits.com is devoted ... occasion dresses for the global clients. All its items ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Bedros Keuilian ... expert; a title he’s earned by founding the fast-selling fitness ... on marketing their businesses. He works with successful boot camp ... blog post on the traits of the most successful boot ... share three important qualities. , “I’ve worked with and coached ...
Breaking Medicine News(10 mins):Health News:Opening-up the stem cell niche 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3
... The Campaign for Tobacco-Free Kids applauds U.S. Senators Carl ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...
... June 11 The following statement of CEO Nancy Brown ... Tobacco Control Act was released today by the American Heart ... bold and courageous step to ensure a healthier future for ... Tobacco Control Act. The legislation will allow us to ...
... Illinois Senators Vote for Historic Bill ... June 11 The Campaign for Tobacco-Free Kids applauds U.S. ... Senate to pass historic legislation that gives the U.S. Food ... the authority to crack down on tobacco marketing and sales ...
... for Tobacco-Free Kids applauds Senate Majority Leader Harry Reid for ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...
... June 12, 2009 , , LANCASTER, Pa., June 11 ... financial results for the third quarter ended May 3, 2009. , ... ended May 3, 2009 were approximately $41.8 million, up 25% as ... 2008. , , Income from continuing operations before income taxes ...
... Zix Corporation (ZixCorp(R)), (Nasdaq: ... payor sponsored e-Prescribing services, announced today that it has ... of Directors in investigating strategic alternatives for maximizing the ... review may result in a partnership, joint venture, the ...
Cached Medicine News:Health News:Senators Levin and Stabenow Vote to Protect America's Kids from Tobacco 2Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 2Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 3Health News:Senator Reid Leads Fight to Protect America's Kids From Tobacco 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 3Health News:Herley Industries, Inc. Reports Third Quarter Earnings 4Health News:Herley Industries, Inc. Reports Third Quarter Earnings 5Health News:Herley Industries, Inc. Reports Third Quarter Earnings 6Health News:Herley Industries, Inc. Reports Third Quarter Earnings 7Health News:Herley Industries, Inc. Reports Third Quarter Earnings 8Health News:Herley Industries, Inc. Reports Third Quarter Earnings 9Health News:Herley Industries, Inc. Reports Third Quarter Earnings 10Health News:Herley Industries, Inc. Reports Third Quarter Earnings 11Health News:Herley Industries, Inc. Reports Third Quarter Earnings 12Health News:Zix Corporation Announces Review of Strategic Alternatives for e-Prescribing Business 2
... The NMP22® Test Kit is a quantitative ... NMP22 protein. Healthy individuals generally have very small ... the level of NMP22 protein is often elevated ... even at early stages of the disease. The ...
... connect an infusion bag ... and then to a ... to conduct urodynamics studies. ... Medical Technologies infusion pumps. ...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
... Used for cystometry and urethral pressure ... for faster filling of the bladder ... Dual lumen catheter construction allows the ... is performed. Triple lumen catheter construction ...
Medicine Products: